Quick Answer
AGIOS PHARMACEUTICALS, INC. reported Operating Income Loss of -$472.13 million for the year ending 2025.
- AGIOS PHARMACEUTICALS, INC. showed a decrease of -10.9% in Operating Income Loss from 2024 to 2025.
- This data is from AGIOS PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$12.28 million | Q2 2014: -$18.33 million | Q3 2014: $3.21 million | Q4 2014: -$26.73 million | Q1 2015: -$5.20 million | Q2 2015: -$32.13 million | Q3 2015: -$40.48 million | Q4 2015: -$40.90 million | Q1 2016: -$23.59 million | Q2 2016: -$56.47 million | Q3 2016: -$63.51 million | Q4 2016: -$57.41 million | Q1 2017: -$67.05 million | Q2 2017: -$84.60 million | Q3 2017: -$79.02 million | Q4 2017: -$90.13 million | Q1 2018: -$94.01 million | Q2 2018: -$72.95 million | Q3 2018: -$99.16 million | Q4 2018: -$96.36 million | Q1 2019: -$97.48 million | Q2 2019: -$113.86 million | Q3 2019: -$109.06 million | Q4 2019: -$105.93 million | Q1 2020: -$87.03 million | Q2 2020: -$83.26 million | Q3 2020: -$80.29 million | Q4 2020: -$92.43 million | Q1 2021: -$91.22 million | Q2 2021: -$91.22 million | Q3 2021: -$91.15 million | Q1 2022: -$101.15 million | Q2 2022: -$97.64 million | Q3 2022: -$91.09 million | Q1 2023: -$90.61 million | Q2 2023: -$93.70 million | Q3 2023: -$100.90 million | Q1 2024: -$92.07 million | Q2 2024: -$105.82 million | Q3 2024: -$102.81 million | Q1 2025: -$106.63 million | Q2 2025: -$127.06 million | Q3 2025: -$116.87 million.
- Over the full 15 years of available data (2011 to 2025), AGIOS PHARMACEUTICALS, INC.'s Operating Income Loss has declined by 2,738.9%.
- Historical annual values: Fiscal year 2025: -$472.13 million | Fiscal year 2024: -$425.74 million | Fiscal year 2023: -$391.49 million | Fiscal year 2022: -$389.05 million | Fiscal year 2021: -$378.42 million | Fiscal year 2020: -$335.92 million | Fiscal year 2019: -$316.27 million | Fiscal year 2018: -$362.48 million | Fiscal year 2017: -$320.79 million | Fiscal year 2016: -$200.99 million | Fiscal year 2015: -$118.70 million | Fiscal year 2014: -$54.13 million | Fiscal year 2013: -$38.88 million | Fiscal year 2012: -$23.00 million | Fiscal year 2011: -$16.63 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: